Patents by Inventor Ward C. Tucker

Ward C. Tucker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200291065
    Abstract: Compositions and methods are described in which a primary detergent or surfactant in an aqueous solution is removed by the addition of a secondary detergent or surfactant in concentrations that exceed the critical micellar concentration (CMC) of the secondary detergent or surfactant. These compositions and methods are particularly applicable to protein-containing solutions. Typical primary detergents/surfactants include polysorbate 20, polysorbate 80, and Triton X-100. Suitable secondary detergents or surfactants can be ionic, nonionic, or zwitterionic. Typical secondary detergents/surfactants include, but are not limited to, galactoside detergents (e.g. octyl-?-galactoside), glucamide detergents (e.g. MEGA 8, MEGA 9, MEGA 10), cholamide detergents (e.g. CHAPS, CHAPSO, BIGCHAPS), and sulfobetaine detergents (such as sulfobetaine 3-10).
    Type: Application
    Filed: March 13, 2020
    Publication date: September 17, 2020
    Inventors: Francis Mark DUNNING, Ward C. Tucker
  • Patent number: 10768178
    Abstract: Methods for a cell-based assay for Botulinum neurotoxin are provided in which a transfected cell that produces a reporting peptide is contacted with a Botulinum neurotoxin in media having a sub-physiological osmolarity and a temperature that is above physiological temperature. This combination provides an unexpected synergistic effect in reducing the EC50 of the cell-based assay relative to an analogous cell-based assay performed at physiological osmolarity and temperature.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 8, 2020
    Assignee: BioMadison, Inc.
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Publication number: 20200109174
    Abstract: Reporting constructs for characterizing Botulinum neurotoxin protease activity and suitable for use in a cell-based assay are provided. The reporting construct can be a single recombinant hybrid protein or a pair of recombinant hybrid proteins that act in concert. The recombinant hybrid protein(s) include a fluorophore and an N-terminal non-peptide membrane anchoring portion. The recombinant hybrid protein or at least one of a pair of recombinant hybrid proteins that act in concert include a Botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 9, 2020
    Inventors: Ward C. Tucker, Francis Mark Dunning
  • Patent number: 10508135
    Abstract: Compositions and methods for analyzing protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity, using a cell based assay are provided. Cells express at least two recombinant hybrid proteins each of which includes a fluorophore and a membrane anchoring peptide, and at least one of which includes a BoNT protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage. Analysis is performed by monitoring fluorescence following exposure to a BoNT. The fluorophores are positioned so that no useful FRET occurs between them, permitting fluorescence produced by the non-released fluorophore to be used in data normalization.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 17, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Publication number: 20190339273
    Abstract: Compositions and methods for determining the efficacy and/or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and frozen. Upon thawing aliquots these cells are activated by exposure to a series of dilutions of q vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and/or potency.
    Type: Application
    Filed: April 17, 2019
    Publication date: November 7, 2019
    Inventor: Ward C Tucker
  • Publication number: 20190331665
    Abstract: Compositions and methods are provided that improve detection of botulinum neurotoxins in cell-based assays. In one aspect an isoquinolynyl compound can be used to enhance the sensitivity of both Förster resonance energy transfer (FRET) and non-FRET cell-based assays. Osmolarity of the cell culture media can be adjusted to optimize the effect of the compound. In that subject matter an environment cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. Where the environment is a cell, the cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Application
    Filed: May 9, 2019
    Publication date: October 31, 2019
    Inventors: Tim Piazza, Ward C Tucker
  • Patent number: 10317394
    Abstract: Apparatus, systems and methods can provide improved detection of botulinum neurotoxins. In one aspect an isoquinolynyl compound can be used to enhance the sensitivity of both Förster resonance energy transfer (FRET) and non-FRET cell-based assays. In another aspect, non-FRET assays and constructs utilize a reporter that is not coupled with the second fluorophore in a manner that produces significant FRET. In that subject matter an environment cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. Where the environment is a cell, the cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: June 11, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Timothy M. Piazza, Ward C. Tucker
  • Publication number: 20190153037
    Abstract: Compositions and methods for analyzing protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity, using a cell based assay are provided. Cells express at least two recombinant hybrid proteins each of which includes a fluorophore and a membrane anchoring peptide, and at least one of which includes a BoNT protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage. Analysis is performed by monitoring fluorescence following exposure to a BoNT. The fluorophores are positioned so that no useful FRET occurs between them, permitting fluorescence produced by the non-released fluorophore to be used in data normalization.
    Type: Application
    Filed: February 4, 2019
    Publication date: May 23, 2019
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Publication number: 20190145974
    Abstract: Methods for a cell-based assay for Botulinum neurotoxin are provided in which a transfected cell that produces a reporting peptide is contacted with a Botulinum neurotoxin in media having a sub-physiological osmolarity and a temperature that is above physiological temperature. This combination provides an unexpected synergistic effect in reducing the EC50 of the cell-based assay relative to an analogous cell-based assay performed at physiological osmolarity and temperature.
    Type: Application
    Filed: January 11, 2019
    Publication date: May 16, 2019
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Patent number: 10246492
    Abstract: Compositions and methods for analyzing intracellular BoNT protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity are provided. Cells express at least two recombinant hybrid proteins each of which includes a fluorophore and a membrane anchoring peptide, and at least one of which includes a BoNT protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage. Analysis is performed by monitoring fluorescence following exposure to a BoNT.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: April 2, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Francis Mark Dunning
  • Patent number: 10191051
    Abstract: Methods and compositions are provided where a transfected cell that produces a hybrid protein with a reporter-containing portion and a botulinum toxin cleavage site is contacted with a botulinum toxin in media having a reduced sodium concentration, thereby increasing the sensitivity. Such media can also be used in combination with elevated cell culture temperatures. Kits that include such media and a botulinum toxin are also described.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 29, 2019
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Patent number: 10100094
    Abstract: Compositions for characterization of Botulinum toxin (BoNT) are described that include a genetically modified cell that is transfected with an artificial construct comprising a nucleic acid sequence that encodes for a hybrid protein having (a) a reporter-containing portion chemically coupled to (b) a cleavage site and (c) a control fluorophore. The cleavage site interacts with a BoNT in a manner that cleaves the reporter-containing portion from remainder of the construct. The cleaved portion is destroyed or otherwise degraded by the local environment, and presence of BoNT is evidenced by reduction in signal from the reporter. The cleavage sequence is all or part of a SNARE protein, the cleavable reporter-containing portion is preferably Yellow Fluorescent Protein (YFP), Citrine, Venus, or a YPet protein and the control fluorophore is preferably CFP, mStrawberry, or a mCherry protein.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: October 16, 2018
    Assignee: BioMadison, Inc.
    Inventors: Dhammika Atapattu, Ward C. Tucker
  • Publication number: 20180072780
    Abstract: Compositions for characterization of Botulinum toxin (BoNT) are described that include a genetically modified cell that is transfected with an artificial construct comprising a nucleic acid sequence that encodes for a hybrid protein having (a) a reporter-containing portion chemically coupled to (b) a cleavage site and (c) a control fluorophore. The cleavage site interacts with a BoNT in a manner that cleaves the reporter-containing portion from remainder of the construct. The cleaved portion is destroyed or otherwise degraded by the local environment, and presence of BoNT is evidenced by reduction in signal from the reporter. The cleavage sequence is all or part of a SNARE protein, the cleavable reporter-containing portion is preferably Yellow Fluorescent Protein (YFP), Citrine, Venus, or a YPet protein and the control fluorophore is preferably CFP, mStrawberry, or a mCherry protein.
    Type: Application
    Filed: November 17, 2017
    Publication date: March 15, 2018
    Inventors: Dhammika ATAPATTU, Ward C. TUCKER
  • Publication number: 20180074044
    Abstract: Compositions and methods for improved cell-based methods of characterizing botulinum neurotoxins are provided. Cells utilized in these methods include a reporting construct that is cleaved following uptake and processing of botulinum neurotoxin by the cell, resulting in proteolysis of the portion of the reporting construct that is released following cleavage. The released portion includes a fluorophore and amino acid substitutions or sequences that enhance the rate of proteolysis. A pair of reporting constructs can be utilized in which one member of the pair is modified to resist cleavage by the botulinum neurotoxin while co-localizing with the remaining member of the pair.
    Type: Application
    Filed: May 16, 2017
    Publication date: March 15, 2018
    Inventors: Timothy Piazza, Francis Mark Dunning, Ward C. Tucker
  • Publication number: 20170097350
    Abstract: Methods and compositions are provided where a transfected cell that produces a hybrid protein with a reporter-containing portion and a botulinum toxin cleavage site is contacted with a botulinum toxin in media having a reduced sodium concentration, thereby increasing the sensitivity. Such media can also be used in combination with elevated cell culture temperatures. Kits that include such media and a botulinum toxin are also described.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Inventors: Ward C. Tucker, Timothy M. Piazza
  • Patent number: 9526345
    Abstract: Methods and compositions are provided where a transfected cell that produces a hybrid protein with a reporter-containing portion and a botulinum toxin cleavage site is contacted with a botulinum toxin at elevated temperatures and/or in media having a reduced sodium concentration. Kits that include such media and a botulinum toxin are also described.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: December 27, 2016
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Tim Piazza
  • Patent number: 9453254
    Abstract: Compositions and methods for analyzing intracellular BoNT protease activity, and especially BoNT/B, BoNT/G, BoNT/D, and/or BoNT/F protease activity are provided. Most preferably, cells express one or more recombinant hybrid proteins that include one or more fluorescent proteins and at least one BoNT protease recognition and cleavage sequence, and analysis is performed using FRET analysis.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: September 27, 2016
    Assignee: BIOMADISON, INC.
    Inventors: Ward C. Tucker, Füsûn N. Zeytin
  • Publication number: 20160229898
    Abstract: Compositions for characterization of Botulinum toxin (BoNT) are described that include a genetically modified cell that is transfected with an artificial construct comprising a nucleic acid sequence that encodes for a hybrid protein having (a) a reporter-containing portion chemically coupled to (b) a cleavage site and (c) a control fluorophore. The cleavage site interacts with a BoNT in a manner that cleaves the reporter-containing portion from remainder of the construct. The cleaved portion is destroyed or otherwise degraded by the local environment, and presence of BoNT is evidenced by reduction in signal from the reporter. The cleavage sequence is all or part of a SNARE protein, the cleavable reporter-containing portion is preferably Yellow Fluorescent Protein (YFP), Citrine, Venus, or a YPet protein and the control fluorophore is preferably CFP, mStrawberry, or a mCherry protein.
    Type: Application
    Filed: February 8, 2016
    Publication date: August 11, 2016
    Inventors: Dhammika ATAPATTU, Ward C. TUCKER
  • Publication number: 20160223524
    Abstract: Apparatus, systems and methods can provide improved detection of botulinum neurotoxins. In one aspect an isoquinolynyl compound can be used to enhance the sensitivity of both Förster resonance energy transfer (FRET) and non-FRET cell-based assays. In another aspect, non-FRET assays and constructs utilize a reporter that is not coupled with the second fluorophore in a manner that produces significant FRET. In that subject matter an environment cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. Where the environment is a cell, the cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Application
    Filed: February 23, 2016
    Publication date: August 4, 2016
    Inventors: Timothy M. Piazza, Ward C. Tucker
  • Patent number: 9303285
    Abstract: Apparatus, systems and methods can provide improved detection of botulinum neurotoxins. In one aspect an isoquinolynyl compound can be used to enhance the sensitivity of both Förster resonance energy transfer (FRET) and non-FRET cell-based assays. In another aspect, non-FRET assays and constructs utilize a reporter that is not coupled with the second fluorophore in a manner that produces significant FRET. In that subject matter an environment cell can include an enzyme that facilitates degradation of the reporter significantly faster after the cleavage than before the cleavage, and presence of the Botulinum toxin correlates with reduction of the signal from a baseline signal. Where the environment is a cell, the cell can advantageously express both the construct that includes the reporter, and an enzyme that facilitates the degradation.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: April 5, 2016
    Assignee: BIOMADISON, INC.
    Inventors: Timothy M Piazza, Ward C. Tucker